Hologic, Inc. (NASDAQ:HOLX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Hologic, Inc. (NASDAQ:HOLX) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are currently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $87.50.

Several research firms have weighed in on HOLX. Evercore ISI boosted their price target on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. Citigroup lowered Hologic from a “buy” rating to a “neutral” rating and dropped their target price for the company from $95.00 to $85.00 in a research report on Tuesday, October 1st. JPMorgan Chase & Co. raised their price target on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th. Leerink Partners dropped their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Finally, Stephens reissued an “overweight” rating and set a $92.00 target price on shares of Hologic in a report on Tuesday, July 30th.

Hologic Trading Up 1.8 %

NASDAQ HOLX opened at $82.33 on Friday. The stock has a market cap of $19.12 billion, a P/E ratio of 28.00, a P/E/G ratio of 2.94 and a beta of 0.98. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. Hologic has a 12-month low of $66.53 and a 12-month high of $84.67. The company has a fifty day simple moving average of $80.99 and a two-hundred day simple moving average of $77.98.

Insiders Place Their Bets

In related news, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the sale, the insider now owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.75% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Hologic

Several large investors have recently bought and sold shares of the company. Innealta Capital LLC acquired a new stake in shares of Hologic in the second quarter worth approximately $25,000. Wolff Wiese Magana LLC purchased a new stake in shares of Hologic during the third quarter worth $25,000. iA Global Asset Management Inc. acquired a new stake in shares of Hologic in the first quarter valued at about $37,000. Sunbelt Securities Inc. acquired a new position in Hologic during the second quarter worth about $37,000. Finally, Cromwell Holdings LLC boosted its position in Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 416 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.